Items where Division is "Current Faculties > Faculty of Medicine > Cancer Sciences > Immunology > Antibody and Vaccine Group
Cancer Sciences > Immunology > Antibody and Vaccine Group" and Year is 2025
 | Up a level |
Number of items: 19.
B
Author correction: development and characterisation of a novel 3D in vitro model of obesity-associated breast cancer as a tool for drug testing - Rhianna R.R. Blyth, Stephanie A. Laversin, Russell B. Foxall, Constantinos Savva, Ellen Copson, Ramsey I. Cutress, Charles N. Birts and Stephen A. Beers
Type: Letter
| 2025
Development and characterisation of a novel 3D in vitro model of obesity-associated breast cancer as a tool for drug testing - Rhianna R.R. Blyth, Stèphanie A. Laversin, Russell B. Foxall, Constantinos Savva, Ellen Copson, Ramsey I. Cutress, Charles N. Birts and Stephen A. Beers
Type: Article
| 2025
CD27 agonist antibodies mediate clinical responses through intratumoral stimulation in B-cell malignancies: multicenter RiVa trial - Lara E. Buermann, Louise Stanton and Matthew J.J. Rose-Zerilli
Type: Article
| 2025
| Item availability restricted.
C
The ETS-family transcription factor PU.1 is a critical regulator of the inhibitory Fcγ receptor IIB expression in humans - Matthew J. Carter, Yury D. Bogdanov, Rosanna C. Smith, Kerry L. Cox, Sarah Frampton, Lili Ferson, Russell B. Foxall, Khiyam Hussain, Jonathan C. Strefford, Stephen A. Beers and Mark S. Cragg
Type: Article
| 2025
CenSegNet: a generalist high-throughput deep learning framework for centrosome phenotyping at spatial and single-cell resolution in heterogeneous tissues - Jiaoqi Cheng, Keqiang Fan, Miles Bailey, Xin Du, Rajesh Jena, Costantinos Savva, Mengyang Gou, Ramsey Cutress, Stephen Beers, Xiaohao Cai and Salah Elias
Type: UNSPECIFIED
| 2025
| bioRxiv
D
Evidence of focusing the MHC class I immunopeptidome by tapasin - Rachel Darley, Patricia T. Illing, Patrick Duriez, Alistair Bailey, Anthony W. Purcell, Andy van Hateren and Tim Elliott
Type: Article
| 2025
Accelerating drug development for neuroblastoma: consensus statement from the third neuroblastoma drug development strategy forum - Steve Dubois, Lucas Moreno and John Anderson
Type: Review
| 2025
| Item availability restricted.
E
Structure-guided disulfide engineering restricts antibody conformation to elicit TNFR agonism - Isabel G. Elliott, Hayden Fisher, H.T. Claude Chan, Tatyana Inzhelevskaya, C. Ian Mockridge, Christine A. Penfold, Patrick J. Duriez, Christian M. Orr, Julie Herniman, Kri T.J. Müller, Jonathan W. Essex, Mark S. Cragg and Ivo Tews
Type: Article
| 2025
G
Theragnostics for neuroblastoma: making molecular radiotherapy work better - Peter J. Gawne, Helen E. Bryant, Steven G. DuBois, Sally L. George, Juliet Gray, Leona Knox, Kyle B. Matchett, Connie Peet, Katherine A. Vallis, Hugh J. Wallace, Simon Wan and Mark N. Gaze
Type: Review
| 2025
CD40L and IL-4 suppress NK cell-mediated antibody-dependent cellular cytotoxicity through the HLA-E:NKG2A axis - Lara V. Graham, Ludmila Horehajova, Marco V. Haselager, Jack G. Fisher, Jamie Lee Roos, Russell B. Foxall, Mel John, Kerry L. Cox, Robert J. Oldham, Martin C. Taylor, Margaret Ashton-Key, Ben Sale, Laura G. Bartlett, Ali Roghanian, Eric Eldering, Andres F. Vallejo, Francesco Forconi, Salim I. Khakoo, Mark S. Cragg and Matthew D. Blunt
Type: Article
| 2025
H
Droplet microfluidic hydrogen/deuterium exchange for investigating protein dynamics with millisecond precision - Dietmar Hammerschmid, Alistair Bailey, Jakub Sys, Simon Lane, Max Saito, Theodore Hornsey, Niall Hanrahan, Andy Van Hateren, Howard Broughton, Alfonso Espada, Eamonn Reading and Jonathan West
Type: UNSPECIFIED
| 2025
| ChemRxiv
K
Defective neutrophil clearance in JAK2V617F myeloproliferative neoplasms drives myelofibrosis via immune checkpoint CD24 - Eman Khatib-Massalha, Christian Andrea Di Buduo, Agathe L Chédeville, Ya-Hsuan Ho, Yexuan Zhu, Elodie Grockowiak, Yuki Date, Lam Tan Khuat, Zijian Fang, Jose Quesada-Salas, Eva Carrillo Félez, Matteo Migliavacca, Isabel Montero, José Antonio Pérez-Simón, Alessandra Balduini and Simón Méndez-Ferrer
Type: Article
| 2025
L
Dinutuximab beta versus naxitamab in the treatment of re-lapsed/refractory neuroblastoma in patients with stable disease, minor response or partial response and disease in bone or bone marrow: systematic review and matching-adjusted indirect comparison - Holger N. Lode, Przemysław Holko and Aleksandra Wieczorek
Type: Article
| 2025
Fcγ receptor polymorphism in relapsed/refractory high-risk neuroblastoma patients correlates with outcomes in the SIOPEN dinutuximab beta long-term infusion trial - Holger N. Lode, Nikolai Siebert and Dominique Valteau-Couanet
Type: Article
| 2025
S
FcγRIIB (CD32B) antibodies enhance immune responses through activating FcγRs - Alexander P. Simpson, Robert J. Oldham, Kerry L. Cox, Martin C. Taylor, Sonya James, Yury Bogdanov, Martin J. Glennie, Bjorn Frendeus, Mark S. Cragg and Ali Roghanian
Type: Article
| 2025
T
The origin, diagnosis, and prognosis of oligomannose-type diffuse large B-cell lymphoma - Dylan James Tatterton, Maddy L. Newby, Joel D. Allen, Benjamin J. Sale, Giorgia Chiodin, Patrick J. Duriez, John Butler, Katy J. McCann, David W. Scott, Ryan D. Morin, Kostiantyn Dreval, Andrew J. Davies, Dean Bryant, Max Crispin and Francesco Forconi
Type: Article
| 2025
| Item availability restricted.
Small but mighty: the power of microcrystals in structural biology - Courtney J. Tremlett, Jack Stubbs, William S. Stuart, Patrick D. Shaw Stewart, Jonathan West, Allen M. Orville, Ivo Tews and Nicholas J. Harmer
Type: Article
| 2025
W
Red-light-induced cysteine modifications suitable for protein labeling - Tomasz Wdowik, Egor Fedorov, Tina-Thien Ho, Patrick Duriez, Eugen Stulz and Dorota Gryko
Type: Article
| 2025
Patients, parents and professional perspectives on molecular radiotherapy for neuroblastoma and paediatric neuroendocrine cancers - Lisa Whittaker, Leona Knox, Connie Peet, Aine O'Donovan, Juliet Gray, Simon Wan, Mark N. Gaze and Glenn Flux
Type: Article
| 2025
| Item availability restricted.